Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5679485 | 0.99 | ACHE (0.57) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL5722321 | 0.89 | HSD17B10 (0.62) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL5722323 | 0.89 | HSD17B10 (0.62) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL4637023 | 0.88 | CA1 (0.47) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL7545790 | 0.88 | HSD17B10 (0.61) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL7545794 | 0.88 | HSD17B10 (0.61) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL10357226 | 0.83 | HSD17B10 (0.62) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL9518883 | 0.83 | ACHE (0.58) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL5679478 | 0.83 | ACHE (0.58) | ACHEDRD2DRD3HSD17B10ALOX15 | |
| SCHEMBL5681817 | 0.83 | ACHE (0.58) | ACHEDRD2DRD3HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030160-B2 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2006-04-18 | — | — | US | disclosed |
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | SANOFI-AVENTIS (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1292572-B1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI SYNTHELABO (FR) | 2004-02-18 | — | — | EP | disclosed |
| EP-1292572-A1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001094307-A1 | PROPANOLAMINOTETRALINES, PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034070-A1 | Propanolaminotetralines, preparation thereof and compositions containing same | ADRB3, ADRB1, ADRB2 | ACHE 79/4885DRD2 386/4885DRD3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.